Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan van Lunzen

Showing results (41-50 of 112) with videos related to

Pageof 12
Sort By:
Plos One|November 5, 2014
CD161+ MAIT cells are severely reduced in peripheral blood and lymph nodes of HIV-infected individuals independently of disease progressionJohanna Maria Eberhard, Philip Hartjen, Silke Kummer, et al.
AIDS (London, England)|March 15, 2005
Complement dependent trapping of infectious HIV in human lymphoid tissuesZoltán Bánki, Laco Kacani, Peter Rusert, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 3, 2018
CD32 Expression of Different Memory T Cell Subpopulations in the Blood and Lymph Nodal Tissue of HIV Patients and Healthy Controls Correlates With Immune ActivationMelanie Wittner, Gábor A Dunay, Silke Kummer, et al.
Antiviral Therapy|September 6, 2008
Incidence of abacavir hypersensitivity reactions in euroSIDAWendy P Bannister, Nina Friis-Møller, Amanda Mocroft, et al.
Journal of Virology|May 18, 2007
MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligandsAngela Meier, Galit Alter, Nicole Frahm, et al.
The Journal of Clinical Investigation|March 20, 2002
Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infectionMarcus Altfeld, Jan van Lunzen, Nicole Frahm, et al.
HIV Clinical Trials|May 31, 2017
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PIJose R Arribas, Edwin DeJesus, Jan van Lunzen, et al.
AIDS (London, England)|December 23, 2008
Epidemiologically linked transmission of HIV-1 illustrates the impact of host genetics on virological outcomeHendrik Streeck, Heiko Jessen, Claudia Kuecherer, et al.
AIDS (London, England)|July 11, 2008
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48Roberto Ortiz, Edwin Dejesus, Homayoon Khanlou, et al.
Antiviral Therapy|March 19, 2013
Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional studyAlexander Zoufaly, Quirine Fillekes, Raffaela Hammerl, et al.
Pageof 12

Showing results (41-50 of 112) with videos related to

Sort By:
Pageof 12
Plos One|November 5, 2014
CD161+ MAIT cells are severely reduced in peripheral blood and lymph nodes of HIV-infected individuals independently of disease progressionJohanna Maria Eberhard, Philip Hartjen, Silke Kummer, et al.
AIDS (London, England)|March 15, 2005
Complement dependent trapping of infectious HIV in human lymphoid tissuesZoltán Bánki, Laco Kacani, Peter Rusert, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 3, 2018
CD32 Expression of Different Memory T Cell Subpopulations in the Blood and Lymph Nodal Tissue of HIV Patients and Healthy Controls Correlates With Immune ActivationMelanie Wittner, Gábor A Dunay, Silke Kummer, et al.
Antiviral Therapy|September 6, 2008
Incidence of abacavir hypersensitivity reactions in euroSIDAWendy P Bannister, Nina Friis-Møller, Amanda Mocroft, et al.
Journal of Virology|May 18, 2007
MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligandsAngela Meier, Galit Alter, Nicole Frahm, et al.
The Journal of Clinical Investigation|March 20, 2002
Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infectionMarcus Altfeld, Jan van Lunzen, Nicole Frahm, et al.
HIV Clinical Trials|May 31, 2017
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PIJose R Arribas, Edwin DeJesus, Jan van Lunzen, et al.
AIDS (London, England)|December 23, 2008
Epidemiologically linked transmission of HIV-1 illustrates the impact of host genetics on virological outcomeHendrik Streeck, Heiko Jessen, Claudia Kuecherer, et al.
AIDS (London, England)|July 11, 2008
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48Roberto Ortiz, Edwin Dejesus, Homayoon Khanlou, et al.
Antiviral Therapy|March 19, 2013
Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional studyAlexander Zoufaly, Quirine Fillekes, Raffaela Hammerl, et al.
Pageof 12